Literature DB >> 10684946

Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene.

M Laverdière1, J Beaudoin, A Lavigueur.   

Abstract

Alternative splicing occurs in the C-terminal region of the p53 tumor suppressor gene between two alternative 3' splice sites in intron 10. This alternative splicing event has been detected in murine cells, but not in rat or human tissues. In this paper, we have characterized the pattern of p53 alternative splicing in cell lines from five different species. Our results confirm that p53 alternative splicing is species-specific, being detected only in cell lines of rodent origin. Using transient transfection assays, we have established that the rat p53 gene undergoes efficient alternative splicing in both mouse and rat cell lines, thus demonstrating that it has all the necessary cis -acting sequences to be alternatively spliced. In contrast, we were unable to detect any usage of the human alternative 3' splice site under the same experimental conditions. Thus, the low levels or absence of alternatively spliced p53 mRNA in rat and human cell lines seems to be the result of different mechanisms. Our results support the hypothesis that there are species-specific mechanisms implicated in the regulation of p53 activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684946      PMCID: PMC111041          DOI: 10.1093/nar/28.6.1489

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  59 in total

1.  The role of overlapping U1 and U11 5' splice site sequences in a negative regulator of splicing.

Authors:  C S Hibbert; R R Gontarek; K L Beemon
Journal:  RNA       Date:  1999-03       Impact factor: 4.942

2.  Alternatively spliced p53 RNA in transformed and normal cells of different tissue types.

Authors:  K A Han; M F Kulesz-Martin
Journal:  Nucleic Acids Res       Date:  1992-04-25       Impact factor: 16.971

Review 3.  Mechanisms for selecting 5' splice sites in mammalian pre-mRNA splicing.

Authors:  D S Horowitz; A R Krainer
Journal:  Trends Genet       Date:  1994-03       Impact factor: 11.639

4.  Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells.

Authors:  M F Kulesz-Martin; B Lisafeld; H Huang; N D Kisiel; L Lee
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

5.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

6.  High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.

Authors:  A Lavigueur; V Maltby; D Mock; J Rossant; T Pawson; A Bernstein
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

7.  Human erythroid 5-aminolevulinate synthase. Gene structure and species-specific differences in alternative RNA splicing.

Authors:  J G Conboy; T C Cox; S S Bottomley; M J Bawden; B K May
Journal:  J Biol Chem       Date:  1992-09-15       Impact factor: 5.157

8.  Species-specific phosphorylation of mouse and rat p53 in simian virus 40-transformed cells.

Authors:  T Patschinsky; U Knippschild; W Deppert
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

9.  p53-catalyzed annealing of complementary single-stranded nucleic acids.

Authors:  P Oberosler; P Hloch; U Ramsperger; H Stahl
Journal:  EMBO J       Date:  1993-06       Impact factor: 11.598

10.  Species specificity and organ, cellular and subcellular localization of the 100 kDa Ras GTPase activating protein.

Authors:  P Mollat; A Fournier; C Z Yang; E Alsat; Y Zhang; D Evain-Brion; J Grassi; M N Thang
Journal:  J Cell Sci       Date:  1994-03       Impact factor: 5.285

View more
  7 in total

1.  Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation.

Authors:  Min Yang; Jack Wu; Si-Hung Wu; An-Ding Bi; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

2.  Epigenetic mechanisms for breakdown of self-incompatibility in interspecific hybrids.

Authors:  June B Nasrallah; Pei Liu; Susan Sherman-Broyles; Renate Schmidt; Mikhail E Nasrallah
Journal:  Genetics       Date:  2007-01-21       Impact factor: 4.562

3.  Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

Authors:  Steven Yea; Goutham Narla; Xiao Zhao; Rakhi Garg; Sigal Tal-Kremer; Eldad Hod; Augusto Villanueva; Johnny Loke; Mirko Tarocchi; Kunihara Akita; Senji Shirasawa; Takehiko Sasazuki; John A Martignetti; Josep M Llovet; Scott L Friedman
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

4.  Alternative splicing and expression of human and mouse NFAT genes.

Authors:  Hanna Vihma; Priit Pruunsild; Tõnis Timmusk
Journal:  Genomics       Date:  2008-08-26       Impact factor: 5.736

5.  Comparative evolutionary genomics of the HADH2 gene encoding Abeta-binding alcohol dehydrogenase/17beta-hydroxysteroid dehydrogenase type 10 (ABAD/HSD10).

Authors:  Alexandra T Marques; Agostinho Antunes; Pedro A Fernandes; Maria J Ramos
Journal:  BMC Genomics       Date:  2006-08-09       Impact factor: 3.969

6.  Novel isoforms of the sodium channels Nav1.8 and Nav1.5 are produced by a conserved mechanism in mouse and rat.

Authors:  Niall C H Kerr; Fiona E Holmes; David Wynick
Journal:  J Biol Chem       Date:  2004-03-26       Impact factor: 5.157

7.  Spontaneous Transformation of Murine Oviductal Epithelial Cells: A Model System to Investigate the Onset of Fallopian-Derived Tumors.

Authors:  Michael P Endsley; Georgette Moyle-Heyrman; Subbulakshmi Karthikeyan; Daniel D Lantvit; David A Davis; Jian-Jun Wei; Joanna E Burdette
Journal:  Front Oncol       Date:  2015-07-17       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.